We are delighted to announce that Eagle IP has been recognized once more as a Highly Recommended Firm in Patent Prosecution by IAM Patent 1000 for 2025. IAM has highlighted Eagle IP as a “compact yet preeminent ensemble” that is adept at “working as a team on global patent matters” and “effective handling of multi-jurisdictional strategies.”

IAM has further highlighted five individuals from our firm:  Our President and Managing Director, Ms. Jennifer Che as a Highly Recommended Individual, Principal Ms. Yolanda Wang as a Recommended Individual, Principal Ms. Pauli Wong as a Next Generation, and Dr. Jacqueline C Lui and Dr. Ho Chung Lui as Luminaries.

It is with great pride that we have been included in this highest category among just a select few of Hong Kong’s top IP firms. We are deeply grateful to IAM for this recognition of our work. At Eagle IP, we are dedicated to providing exceptional service to our clients by drawing upon our hands-on knowledge of US and Chinese patent law, our proven ability to craft sophisticated and creative patent strategies, and our strong technical expertise. We will continue to build upon these strengths to deliver the highest level of service and support to the innovators who entrust us with protecting their groundbreaking ideas.

As always, a huge THANK YOU to all our clients, mentors, and colleagues who have supported us through the years.

我们的过去活动

Recommended Insights

Foreigners Beware: China Proposes Requiring IP Made Using Exported Chinese Genetic Resources to be Co-Owned by Chinese Collaborators

2023年3月22日
Proposed Examination Guidelines for the New Chinese Patent Law – Topic 2: Genetic Resource Restriction How Will the Tightened Genetic Resource Restrictions Affect Your IP In 2019-2021, China’s Ministry of Science and Technology (“MOST”, or the Science Ministry) established several laws and regulations with respect to biosafety1 and human genetic resources management2 (collectively referred as […]

Is it Sufficient to Claim an Antibody only by Describing its Antigen?

2018年11月12日
Things may be brewing with respect to antibody inventions. Just how much description is sufficient? After losing in the Federal Circuit, Amgen has decided to ask the US Supreme Court to weigh in on a standard that could vastly influence the pharmaceutical and biotech industry. The story relates to Repatha™, an LDL-lowering drug from Amgen […]

China’s Newest Examination Guidelines: Novelty and Inventive Step for Compounds (Part II)

2021年4月29日
This is Part II of a three-part series summarizing the Examination Guidelines that were released by the CNIPA on January 15, 2021, one year to the date of Phase 1 of the US and China Economic and Trade Agreement. That agreement included specific provisions where China "shall permit pharmaceutical patent applicants to rely on supplemental […]

CHINA: New Patent Examination Guidelines Now Available for Public Comment

2021年8月4日
Two months after the new Chinese Patent law came into effect, the CNIPA has released a new set of Patent Examination Guidelines (proposed version) for public comments on Aug 3, 2021. Here are the explanation of the amendments (Chinese only). Here is the full set of proposed amendments (Chinese only). Briefly, the new amendment focuses […]
Top crossarrow-right